Evaluation of the preventive effectiveness of influenza vaccines in St. Petersburg
https://doi.org/10.31631/2073-3046-2020-19-5-76-83
Abstract
Background. The influenza vaccination coverage has steadily increased in the Russian Federation. The introduction of new domestic influenza vaccines into practice and the study of their effectiveness are of great importance for public health. However, a systematic analysis of the effectiveness of vaccines manufactured and used in Russia in recent years has not been performed. The aim ofthe study was to assess the epidemiological effectiveness of three domestic influenza vaccines in St. Petersburg during the 2018–2019 epidemic season.
Material and methods. The organized community of 1892 young students aged 18 to 23 years has been under supervision during the period of time from October 2018 to March 2019. Influenza vaccines Grippol Plus, Sovigripp, and Ultrix were used for vaccination.
Results and discussion. Prophylactic vaccination with influenza vaccines Sovigripp, Grippol Plus and Ultrix in the fall of 2018 led to a decrease in the incidence of influenza and other acute respiratory infections (ARI) by a total of 1.6–3.8 times; a decrease in the incidence of influenza by 2.7–7.1 times; the total protective efficacy of vaccines against influenza and ARI was 52.4%, and against influenza, taking into account laboratory correction, 73.3%.
Conclusions. Under the conditions of the viruses circulating in Russia and in St. Petersburg in the 2018–2019 epidemic season the strains introduced into the composition of influenza vaccines, domestic influenza vaccines were characterized by good tolerance, were safe, areactogenic and had a pronounced protective effect. If the viruses circulating in Russia and in St. Petersburg in the 2018–2019 epidemic season corresponded to the strains introduced into the composition of influenza vaccines, domestic influenza vaccines, showing good tolerance, safety and low reactogenicity, had a pronounced protective effect.
About the Authors
M. K. ErofeevaRussian Federation
Mariana K. Erofeeva – Dr. Sci. (Med.), Head of the Laboratory of Trials of Novel Remedies for Antiviral Protection
prof. Popov street, 15/17, Saint-Petersburg
M. A. Stukova
Russian Federation
Marina A. Stukova – Cand. Sci. (Med.), Head of the Laboratory of vector vaccines
prof. Popov street, 15/17, Saint-Petersburg
E. V. Shakhlanskaya
Russian Federation
Elizaveta V. Shakhlanskaya – Researcher at the Laboratory of Trials of Novel Remedies for Antiviral Protection
prof. Popov street, 15/17, Saint-Petersburg
Zh. V. Buzitskaya
Russian Federation
Zhanna V. Buzitskaya – Cand. Sci. (Biol.), Senior Researcheк of the Laboratory of vectors vaccines
prof. Popov street, 15/17, Saint-Petersburg
V. L. Maksakova
Russian Federation
Velichka L. Maksakova – Cand. Sci. (Med.), Laboratory of Trials of Novel Remedies for Antiviral Protection
prof. Popov street, 15/17, Saint-Petersburg
T. I. Krainova
Russian Federation
Tatyana I. Krainova – Researcher at the Laboratory of Trials of Novel Remedies for Antiviral Protection
prof. Popov street, 15/17, Saint-Petersburg
T. M. Chirkina
Russian Federation
Tatyana M. Chirkina – Cand. Sci. (Med.), аssistant of the Department of Epidemiology
Saint-Petersburg
M. M. Pisareva
Russian Federation
Maria M. Pisareva – Cand. Sci. (Biol.), Leading Researcher, Laboratory of Molecular Biology
prof. Popov street, 15/17, Saint-Petersburg
D. A. Lioznov
Russian Federation
Dmitry A. Lioznov – Dr. Sci. (Med.), Deputy Director of Smorodintsev Research Institute of Influenza, Head of the Department of Infectious Diseases and Epidemiology of First St. Petersburg Pavlov State Medical University
prof. Popov street, 15/17, Saint-Petersburg
References
1. Vikulov GKh. New and recurring respiratory viral infections: diagnostic and therapeutic algorithms. RMJ. Medical Review. 2018;8(I):5–11.
2. Textbook of Influenza. Eds.: Nicholson KG, Webster RG, Hay AJ. Blackwell Science, Oxford. 1998:358–372.
3. Demicheli V, Jefferson T, Ferroni E, Rivetti A., Di Pietrantonj C. Review Vaccines for Preventing Influenza in Healthy Adults Сochrane Database Syst Rev. 2018 Feb 1;2(2):CD001269.
4. Ghendon Y. Vaccination against influenza viruses: Current status. Viral vaccines. Advances in biotechnological processes. Ed.: Mirrahi E. 1990;14:159–201.
5. Vaccine Effectiveness: How Well Do the Flu Vaccines Work? Available at: https://www.cdc.gov/flu/about/qa/vaccineeffect.htm (date of treatment 04/28/2020).
Review
For citations:
Erofeeva M.K., Stukova M.A., Shakhlanskaya E.V., Buzitskaya Zh.V., Maksakova V.L., Krainova T.I., Chirkina T.M., Pisareva M.M., Lioznov D.A. Evaluation of the preventive effectiveness of influenza vaccines in St. Petersburg. Epidemiology and Vaccinal Prevention. 2020;19(5):76-83. (In Russ.) https://doi.org/10.31631/2073-3046-2020-19-5-76-83